Adaptive Biotechnologies Corporation $ADPT Shares Sold by Sumitomo Mitsui Trust Group Inc.

Posted by Geri Gentry on Nov 6th, 2026

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 18.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,087,421 shares of the company’s stock after selling 242,435 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Adaptive Biotechnologies were worth $31,426,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Arizona State Retirement System grew its position in shares of Adaptive Biotechnologies by 1.3% in the second quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock valued at $684,000 after purchasing an additional 416 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Adaptive Biotechnologies by 6.8% during the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after buying an additional 941 shares in the last quarter. Gibbs Wealth Management lifted its position in Adaptive Biotechnologies by 4.6% during the third quarter. Gibbs Wealth Management now owns 26,900 shares of the company’s stock worth $777,000 after buying an additional 1,191 shares in the last quarter. Assetmark Inc. lifted its position in Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after buying an additional 1,401 shares in the last quarter. Finally, Nykredit A S purchased a new position in Adaptive Biotechnologies during the second quarter worth approximately $31,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ADPT shares. TD Cowen boosted their price objective on Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a report on Tuesday, September 22nd. Piper Sandler lifted their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, Guggenheim boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.06.

Read Our Latest Stock Analysis on ADPT

Insider Transactions at Adaptive Biotechnologies

In related news, CEO Chad Robins sold 321,324 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $54,687,391.44. This represents a 12.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert Hershberg sold 30,664 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total value of $748,201.60. Following the sale, the director directly owned 46,683 shares of the company’s stock, valued at approximately $1,139,065.20. This trade represents a 39.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,050,763 shares of company stock valued at $26,806,633 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

Positive Sentiment: Adaptive reported Q3 earnings of $0.02 per share, versus the consensus estimate of a $0.10 loss, and revenue of $83.9 million, above the $71.6 million expected. Management also said the company reached total-company profitability ahead of expectations. Quarterly results
Positive Sentiment: Core MRD revenue grew 44%, and Adaptive raised its 2026 MRD revenue outlook to $276 million–$286 million. The company also outlined a target average selling price of $1,700–$1,800, signaling confidence in continued growth of this business. MRD outlook
Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 plan and retained a substantial stake. The planned nature of the sales may make them less informative about her outlook, though insider selling can draw investor attention. Insider sale report
Negative Sentiment: Despite the quarterly beat, revenue was down 10.7% from a year earlier, and the company continued to report a negative net margin. Investors may look for sustained growth and profitability beyond this quarter. Earnings results

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $26.83 on Friday. The firm has a 50 day simple moving average of $26.39 and a 200-day simple moving average of $19.81. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $30.74. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The stock has a market cap of $4.28 billion, a price-to-earnings ratio of -59.62 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.12. The business had revenue of $83.90 million during the quarter, compared to the consensus estimate of $71.57 million. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.47%. The business’s revenue was down 10.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.06 EPS. On average, analysts expect that Adaptive Biotechnologies Corporation will post -0.40 EPS for the current year.

About Adaptive Biotechnologies

(Free Report)

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.